Skip to main content
Top
Published in: Clinical Reviews in Allergy & Immunology 3/2015

01-12-2015

Ocular Involvement of Behçet’s Syndrome: a Comprehensive Review

Authors: Yilmaz Ozyazgan, Didar Ucar, Gulen Hatemi, Yusuf Yazici

Published in: Clinical Reviews in Allergy & Immunology | Issue 3/2015

Login to get access

Abstract

Behçet’s syndrome (BS) is a vasculitis involving several organ systems including the eyes. Ocular involvement is one of the most disabling complications of BS, causing loss of vision that may progress to blindness if left untreated. The typical form of ocular involvement is a relapsing and remitting panuveitis and retinal vasculitis. Initial attacks may spontaneously improve and subsequently disappear in a few weeks but tend to recur if left untreated. Destructive and recurrent attacks, especially with posterior segment and retina involvement, may cause irreversible ocular structural changes and permanent damage in sensory retina, resulting in loss of vision. The risk of irreversible damage to ocular tissue which may result in loss of vision warrants early and intensive treatment especially in patients at high risk such as young men who tend to follow an aggressive disease course. The management strategy involves rapid suppression of inflammation during the attacks and prevention of recurrent attacks. Local and systemic measures including immunosuppressives, corticosteroids, and biologic agents are used for this purpose. Surgery may be required in selected cases. The prognosis of eye involvement has greatly improved over the last decades with the effective use of immunosuppressives.
Literature
1.
go back to reference Tugal-Tutkun I, Gupta V, Cunningham ET (2013) Differential diagnosis of Behçet uveitis. Ocul Immunol Inflamm 21(5):337–350CrossRefPubMed Tugal-Tutkun I, Gupta V, Cunningham ET (2013) Differential diagnosis of Behçet uveitis. Ocul Immunol Inflamm 21(5):337–350CrossRefPubMed
2.
go back to reference Tugal-Tutkun I, Onal S, Ozyazgan Y, Soylu M, Akman M (2013) Validity and agreement of uveitis experts in interpretation of ocular photographs for diagnosis of Behçet uveitis. Ocul Immunol Inflamm. 2013 Dec 11. [Epub ahead of print] Tugal-Tutkun I, Onal S, Ozyazgan Y, Soylu M, Akman M (2013) Validity and agreement of uveitis experts in interpretation of ocular photographs for diagnosis of Behçet uveitis. Ocul Immunol Inflamm. 2013 Dec 11. [Epub ahead of print]
3.
go back to reference Yurdakul S, Yazıcı Y (2010) Epidmiology of Behçet’s syndrome and regional differences in disease expression. In: Yazıcı H, Yazıcı Y (eds) Behçet’s syndrome. Springer, New York, pp 35–52 Yurdakul S, Yazıcı Y (2010) Epidmiology of Behçet’s syndrome and regional differences in disease expression. In: Yazıcı H, Yazıcı Y (eds) Behçet’s syndrome. Springer, New York, pp 35–52
4.
go back to reference Mishima, Masuda K, Izawa Y, Mochizuki M, Namba K (1979) Behçet’s disease in Japan: ophthalmological aspect. Trans Am Ophthalmol Soc 77:225–279PubMedCentralPubMed Mishima, Masuda K, Izawa Y, Mochizuki M, Namba K (1979) Behçet’s disease in Japan: ophthalmological aspect. Trans Am Ophthalmol Soc 77:225–279PubMedCentralPubMed
5.
go back to reference Yang P, Fang W, Meng Q, Ren Y, Xing L, Kijlstra A (2008) Clinical features of Chinese patients with Behçet’s disease. Ophthalmology 115(2):312–318.e4CrossRefPubMed Yang P, Fang W, Meng Q, Ren Y, Xing L, Kijlstra A (2008) Clinical features of Chinese patients with Behçet’s disease. Ophthalmology 115(2):312–318.e4CrossRefPubMed
6.
go back to reference Yazici H, Fresko I, Yurdakul S (2007) Behçet’s syndrome: disease manifestations, management, and advances in treatment. Nat Clin Pract Rheumatol 3(3):148–155CrossRefPubMed Yazici H, Fresko I, Yurdakul S (2007) Behçet’s syndrome: disease manifestations, management, and advances in treatment. Nat Clin Pract Rheumatol 3(3):148–155CrossRefPubMed
7.
go back to reference Kazokoğlu H, Onal S, Tuğal-Tutkun İ et al (2008) Demographic and clinical features of uveitis in tertiary centers in Turkey. Ophthalmic Epidemiol 15:285–293CrossRefPubMed Kazokoğlu H, Onal S, Tuğal-Tutkun İ et al (2008) Demographic and clinical features of uveitis in tertiary centers in Turkey. Ophthalmic Epidemiol 15:285–293CrossRefPubMed
8.
go back to reference Yazıcı H, Tüzün Y, Pazarlı H et al (1984) Influence of age of onset and patient’s sex on the prevalence and severity of manifestation of Behçet’s syndrome. Ann Rheum Dis 43:783–789PubMedCentralCrossRefPubMed Yazıcı H, Tüzün Y, Pazarlı H et al (1984) Influence of age of onset and patient’s sex on the prevalence and severity of manifestation of Behçet’s syndrome. Ann Rheum Dis 43:783–789PubMedCentralCrossRefPubMed
9.
go back to reference Kural-Seyahi E, Fresko İ, Seyahi N et al (2003) The long-term mortality and morbidity of Behçet’s syndrome: a 2-decade outcome survey of 387 patients followed at a dedicated center. Medicine 82:60–76CrossRefPubMed Kural-Seyahi E, Fresko İ, Seyahi N et al (2003) The long-term mortality and morbidity of Behçet’s syndrome: a 2-decade outcome survey of 387 patients followed at a dedicated center. Medicine 82:60–76CrossRefPubMed
10.
go back to reference Tuğal-Tutkun I, Onal S, Altan-Yaycioğlu R, Hüseyin Altunbaş H, Urgancioğlu M (2004) Uveitis in Behçet disease: an analysis of 880 patients. Am J Ophthalmol 138:373–380CrossRefPubMed Tuğal-Tutkun I, Onal S, Altan-Yaycioğlu R, Hüseyin Altunbaş H, Urgancioğlu M (2004) Uveitis in Behçet disease: an analysis of 880 patients. Am J Ophthalmol 138:373–380CrossRefPubMed
11.
go back to reference Jabs DA, Nussenblatt RB, Rosenbaum JT (2005) Standardization of uveitis nomenclature for reporting clinical data. Results of the First International Workshop. Am J Ophthalmol 140:509–516CrossRefPubMed Jabs DA, Nussenblatt RB, Rosenbaum JT (2005) Standardization of uveitis nomenclature for reporting clinical data. Results of the First International Workshop. Am J Ophthalmol 140:509–516CrossRefPubMed
12.
go back to reference Pazarlı H, Ozyazgan Y, Aktunc T (1989) Clinical observations on hypopyon attacks of Behçet’s disease in Turkey. In: Seventh international conference on Behçet’s disease (abstracts), Rochester. MN. 14–15 Sept Pazarlı H, Ozyazgan Y, Aktunc T (1989) Clinical observations on hypopyon attacks of Behçet’s disease in Turkey. In: Seventh international conference on Behçet’s disease (abstracts), Rochester. MN. 14–15 Sept
13.
go back to reference Nussenblatt RB, Whitcup SM, Palestine AG (2004) Behçet’s disease. In: Nussenblatt RB, Whitcup SM, Palestine AG (eds) Uveitis: fundamentals and clinical practice. Mosby, Philadelphia, pp 350–371 Nussenblatt RB, Whitcup SM, Palestine AG (2004) Behçet’s disease. In: Nussenblatt RB, Whitcup SM, Palestine AG (eds) Uveitis: fundamentals and clinical practice. Mosby, Philadelphia, pp 350–371
15.
go back to reference Mullaney J, Collum LM (1985) Ocular vasculitis in Behçet’s disease: a pathological and immunohistochemical study. Int Ophthalmol 7:183–191CrossRefPubMed Mullaney J, Collum LM (1985) Ocular vasculitis in Behçet’s disease: a pathological and immunohistochemical study. Int Ophthalmol 7:183–191CrossRefPubMed
16.
go back to reference Mamo JG (1970) The rate of visual loss in Behçet’s disease. Arc Ophthalmol 84:451–452CrossRef Mamo JG (1970) The rate of visual loss in Behçet’s disease. Arc Ophthalmol 84:451–452CrossRef
17.
go back to reference Cingu AK, Onal S, Urgancioglu M, Tugal-Tutkun I (2012) Comparison of presenting features and three-year disease course in Turkish patients with Behçet uveitis who presented in the early 1990s and the early 2000s. Ocul Immunol Inflamm 20(6):423–428CrossRefPubMed Cingu AK, Onal S, Urgancioglu M, Tugal-Tutkun I (2012) Comparison of presenting features and three-year disease course in Turkish patients with Behçet uveitis who presented in the early 1990s and the early 2000s. Ocul Immunol Inflamm 20(6):423–428CrossRefPubMed
18.
go back to reference Markomichelakis N, Delicha E, Masselos S, Sfikakis PP (2012) Intravitreal infliximab for sight-threatening relapsing uveitis in Behçet disease: a pilot study in 15 patients. Am J Ophthalmol 154(3):534–541CrossRefPubMed Markomichelakis N, Delicha E, Masselos S, Sfikakis PP (2012) Intravitreal infliximab for sight-threatening relapsing uveitis in Behçet disease: a pilot study in 15 patients. Am J Ophthalmol 154(3):534–541CrossRefPubMed
19.
go back to reference Yazıcı H, Pazarlı H, Barnes CG et al (1990) A controlled trail of azathioprine in Behçet’s syndrome. N England J Med 322:281–285CrossRef Yazıcı H, Pazarlı H, Barnes CG et al (1990) A controlled trail of azathioprine in Behçet’s syndrome. N England J Med 322:281–285CrossRef
20.
go back to reference Hamuryudan V, Ozyazgan Y, Hızlı N et al (1997) Azathioprine in Behçet’s syndrome: effects on long-term prognosis. Arthritis Rheum 40:769–774CrossRefPubMed Hamuryudan V, Ozyazgan Y, Hızlı N et al (1997) Azathioprine in Behçet’s syndrome: effects on long-term prognosis. Arthritis Rheum 40:769–774CrossRefPubMed
21.
go back to reference Ozyazgan Y, Yurdakul S, Yazici H, Tuzun B, Işcimen A, Tuzun Y et al (1992) Low dose cyclosporin A versus pulsed cyclophosphamide in Behçet’s syndrome: a single masked trial. Br J Ophthalmol 76:241–243PubMedCentralCrossRefPubMed Ozyazgan Y, Yurdakul S, Yazici H, Tuzun B, Işcimen A, Tuzun Y et al (1992) Low dose cyclosporin A versus pulsed cyclophosphamide in Behçet’s syndrome: a single masked trial. Br J Ophthalmol 76:241–243PubMedCentralCrossRefPubMed
22.
go back to reference Masuda K, Nakajima A, Urayama A, Nakae K et al (1989) Double-masked trial of cyclosporin versus colchicines and long-term open study of cyclosporin in Behçet’s disease. Lancet 1:1093–1096CrossRefPubMed Masuda K, Nakajima A, Urayama A, Nakae K et al (1989) Double-masked trial of cyclosporin versus colchicines and long-term open study of cyclosporin in Behçet’s disease. Lancet 1:1093–1096CrossRefPubMed
23.
go back to reference BenEzra D, Cohen E, Chajek T et al (1988) Evaluation of conventional therapy versus cyclosporin A in Behçet’s syndrome. Transplant Proc 20(3 Suppl 4):136–143PubMed BenEzra D, Cohen E, Chajek T et al (1988) Evaluation of conventional therapy versus cyclosporin A in Behçet’s syndrome. Transplant Proc 20(3 Suppl 4):136–143PubMed
24.
go back to reference Durand JM, Soubeyrand J (1994) Interferon-alpha 2b for refractory ocular Behçet’s disease. Lancet 344:333CrossRefPubMed Durand JM, Soubeyrand J (1994) Interferon-alpha 2b for refractory ocular Behçet’s disease. Lancet 344:333CrossRefPubMed
25.
go back to reference Kotter I, Eckstein AK, Stübiger N et al (1998) Treatment of ocular symptoms of Behçet’s disease with interferon alpha 2a: a pilot study. Br J Ophthalmol 82:488–494PubMedCentralCrossRefPubMed Kotter I, Eckstein AK, Stübiger N et al (1998) Treatment of ocular symptoms of Behçet’s disease with interferon alpha 2a: a pilot study. Br J Ophthalmol 82:488–494PubMedCentralCrossRefPubMed
26.
go back to reference Kotter I, Zıerhut M, Eckstein AK, VontheinR NT, Gunaydın I et al (2003) Human recombinant interferon alfa-2a for the treatment of Behçet’s disease with sight threatening posterior or panuveitis. Br J Ophthalmol 87:423–431PubMedCentralCrossRefPubMed Kotter I, Zıerhut M, Eckstein AK, VontheinR NT, Gunaydın I et al (2003) Human recombinant interferon alfa-2a for the treatment of Behçet’s disease with sight threatening posterior or panuveitis. Br J Ophthalmol 87:423–431PubMedCentralCrossRefPubMed
27.
go back to reference Kotter I, Deuter C, Stubiger N, Zierhut M (2005) Interferon-a (IFN-a) application versus tumor necrosis factor-a antagonism for ocular Behçet’s disease: focusing more on IFN. J Rheumatol 32:1633PubMed Kotter I, Deuter C, Stubiger N, Zierhut M (2005) Interferon-a (IFN-a) application versus tumor necrosis factor-a antagonism for ocular Behçet’s disease: focusing more on IFN. J Rheumatol 32:1633PubMed
28.
go back to reference Tugal –Tutkun I, Güney–Tefekli E, Urgancioğlu M (2006) Results of interferon-alpha therapy in patients with Behçet’s uveitis. Graefes Arch Clin Exp Ophthalmol 244:1692–1695CrossRefPubMed Tugal –Tutkun I, Güney–Tefekli E, Urgancioğlu M (2006) Results of interferon-alpha therapy in patients with Behçet’s uveitis. Graefes Arch Clin Exp Ophthalmol 244:1692–1695CrossRefPubMed
29.
go back to reference Bodaghi B, Gendron G, Wechsler B (2007) Efficacy of interferon alpha in the treatment of refractory and sight threatening uveitis: a retrospective monocentric study of 45 patients. Br J Ophthalmol 91:335–339PubMedCentralCrossRefPubMed Bodaghi B, Gendron G, Wechsler B (2007) Efficacy of interferon alpha in the treatment of refractory and sight threatening uveitis: a retrospective monocentric study of 45 patients. Br J Ophthalmol 91:335–339PubMedCentralCrossRefPubMed
30.
go back to reference Onal S, Kazokoglu H, Koc A et al (2011) Long-term efficacy and safety of low-dose and dose-escalating interferon alfa-2a therapy in refractory Behçet uveitis. Arch Ophthalmol 129:288–294CrossRefPubMed Onal S, Kazokoglu H, Koc A et al (2011) Long-term efficacy and safety of low-dose and dose-escalating interferon alfa-2a therapy in refractory Behçet uveitis. Arch Ophthalmol 129:288–294CrossRefPubMed
31.
go back to reference Sfikakis PP, Theodossiadis PG, Katsiari CG, Kaklamanis P et al (2001) Effect of infliximab on sight-threatening panuveitis in Behçet’s disease. Lancet 358:295–296CrossRefPubMed Sfikakis PP, Theodossiadis PG, Katsiari CG, Kaklamanis P et al (2001) Effect of infliximab on sight-threatening panuveitis in Behçet’s disease. Lancet 358:295–296CrossRefPubMed
32.
go back to reference Ohno S, Nakamura S, Hori S et al (2004) Efficacy, safety and pharmacokinetics of multiple administration of infliximab in Behçet’s disease with refractory uveoretinitis. J Rheumatol 31:1362–1368PubMed Ohno S, Nakamura S, Hori S et al (2004) Efficacy, safety and pharmacokinetics of multiple administration of infliximab in Behçet’s disease with refractory uveoretinitis. J Rheumatol 31:1362–1368PubMed
33.
go back to reference Tugal-Tutkun I, Mudun A, Urgancıoğlu M et al (2005) Efficacy of infliximab in the treatment of uveitis that is resistant to treatment with the combination of azathioprine, cyclosporine, and corticosteroid in Behçet’s disease: an open-label trial. Arthritis Rheum 52:2478–2484CrossRefPubMed Tugal-Tutkun I, Mudun A, Urgancıoğlu M et al (2005) Efficacy of infliximab in the treatment of uveitis that is resistant to treatment with the combination of azathioprine, cyclosporine, and corticosteroid in Behçet’s disease: an open-label trial. Arthritis Rheum 52:2478–2484CrossRefPubMed
34.
go back to reference Bodaghi B, Bui Quoc E, Wechsler B et al (2005) Therapeutic use of infliximab in sight threatening uveitis: retrospective analysis of efficacy, safety, and limiting factors. Ann Rheum Dis 64:962–964PubMedCentralCrossRefPubMed Bodaghi B, Bui Quoc E, Wechsler B et al (2005) Therapeutic use of infliximab in sight threatening uveitis: retrospective analysis of efficacy, safety, and limiting factors. Ann Rheum Dis 64:962–964PubMedCentralCrossRefPubMed
35.
go back to reference Sfikakis PP, Markomichelakis N, Alpsoy E et al (2007) Anti TNF therapy in the management of Behçet’s disease—review and basis for recommendations. Rheumatology (Oxford) 46:736–741CrossRef Sfikakis PP, Markomichelakis N, Alpsoy E et al (2007) Anti TNF therapy in the management of Behçet’s disease—review and basis for recommendations. Rheumatology (Oxford) 46:736–741CrossRef
36.
go back to reference Mushtaq B, Saeed T, Situnayake RD, Murray PI (2007) Adalimumab for sight-threatening uveitis in Behçet’s disease. Eye 21:824–825CrossRefPubMed Mushtaq B, Saeed T, Situnayake RD, Murray PI (2007) Adalimumab for sight-threatening uveitis in Behçet’s disease. Eye 21:824–825CrossRefPubMed
37.
go back to reference Markomichelakis N, Delicha E, Masselos S, Fragiadaki K, Kaklamanis P, Sfikakis PP (2011) A single infliximab infusion vs corticosteroids for acute panuveitis attacks in Behçet’s disease: a comparative 4-week study. Rheumatology (Oxford) 50(3):593–597CrossRef Markomichelakis N, Delicha E, Masselos S, Fragiadaki K, Kaklamanis P, Sfikakis PP (2011) A single infliximab infusion vs corticosteroids for acute panuveitis attacks in Behçet’s disease: a comparative 4-week study. Rheumatology (Oxford) 50(3):593–597CrossRef
38.
go back to reference Okada AA, Goto H, Ohno S, Mochizuki M (2012) Multicenter study of infliximab for refractory uveoretinitis in Behçet disease. Arch Ophthalmol 130(5):592–598CrossRefPubMed Okada AA, Goto H, Ohno S, Mochizuki M (2012) Multicenter study of infliximab for refractory uveoretinitis in Behçet disease. Arch Ophthalmol 130(5):592–598CrossRefPubMed
39.
go back to reference Kawaguchi T, Sugita S, Yamada Y, Miyanaga M, Mochizuki M (2010) Regression of optic disc neovascularization in patients with Behçet’s uveoretinitis after infliximab therapy. J Ocul Pharmacol Ther 26(6):627–630CrossRefPubMed Kawaguchi T, Sugita S, Yamada Y, Miyanaga M, Mochizuki M (2010) Regression of optic disc neovascularization in patients with Behçet’s uveoretinitis after infliximab therapy. J Ocul Pharmacol Ther 26(6):627–630CrossRefPubMed
40.
go back to reference Keino H, Okada AA, Watanabe T, Taki W (2011) Decreased ocular inflammatory attacks and background retinal and disc vascular leakage in patients with Behcet’s disease on infliximab therapy. Br J Ophthalmol 95(9):1245–1250CrossRefPubMed Keino H, Okada AA, Watanabe T, Taki W (2011) Decreased ocular inflammatory attacks and background retinal and disc vascular leakage in patients with Behcet’s disease on infliximab therapy. Br J Ophthalmol 95(9):1245–1250CrossRefPubMed
41.
go back to reference Mushtaq B, Saeed T, Situnayake RD, Murray PI (2007) Adalimumab for sight-threatening uveitis in Behçet’s disease. Eye (Lond) 21(6):824–825CrossRef Mushtaq B, Saeed T, Situnayake RD, Murray PI (2007) Adalimumab for sight-threatening uveitis in Behçet’s disease. Eye (Lond) 21(6):824–825CrossRef
42.
go back to reference Bawazeer A, Raffa LH, Nizamuddin SH (2010) Clinical experience with adalimumab in the treatment of ocular Behçet disease. Ocul Immunol Inflamm 18(3):226–232CrossRefPubMed Bawazeer A, Raffa LH, Nizamuddin SH (2010) Clinical experience with adalimumab in the treatment of ocular Behçet disease. Ocul Immunol Inflamm 18(3):226–232CrossRefPubMed
43.
go back to reference Gül A, Tugal-Tutkun I, Dinarello CA, Reznikov L, Esen BA, Mirza A, Scannon P, Solinger A (2012) Interleukin-1β-regulating antibody XOMA 052 (gevokizumab) in the treatment of acute exacerbations of resistant uveitis of Behcet’s disease: an open-label pilot study. Ann Rheum Dis 71(4):563–566CrossRefPubMed Gül A, Tugal-Tutkun I, Dinarello CA, Reznikov L, Esen BA, Mirza A, Scannon P, Solinger A (2012) Interleukin-1β-regulating antibody XOMA 052 (gevokizumab) in the treatment of acute exacerbations of resistant uveitis of Behcet’s disease: an open-label pilot study. Ann Rheum Dis 71(4):563–566CrossRefPubMed
44.
go back to reference Emmi G, Silvestri E, Cameli AM, Bacherini D, Vannozzi L, Squatrito D, Emmi L (2013) Anakinra for resistant Behçet uveitis: why not? Clin Exp Rheumatol 31(3 Suppl 77):152–153PubMed Emmi G, Silvestri E, Cameli AM, Bacherini D, Vannozzi L, Squatrito D, Emmi L (2013) Anakinra for resistant Behçet uveitis: why not? Clin Exp Rheumatol 31(3 Suppl 77):152–153PubMed
45.
go back to reference Ugurlu S, Ucar D, Seyahi E, Hatemi G, Yurdakul S (2012) Canakinumab in a patient with juvenile Behcet’s syndrome with refractory eye disease. Ann Rheum Dis 71(9):1589–1591CrossRefPubMed Ugurlu S, Ucar D, Seyahi E, Hatemi G, Yurdakul S (2012) Canakinumab in a patient with juvenile Behcet’s syndrome with refractory eye disease. Ann Rheum Dis 71(9):1589–1591CrossRefPubMed
Metadata
Title
Ocular Involvement of Behçet’s Syndrome: a Comprehensive Review
Authors
Yilmaz Ozyazgan
Didar Ucar
Gulen Hatemi
Yusuf Yazici
Publication date
01-12-2015
Publisher
Springer US
Published in
Clinical Reviews in Allergy & Immunology / Issue 3/2015
Print ISSN: 1080-0549
Electronic ISSN: 1559-0267
DOI
https://doi.org/10.1007/s12016-014-8425-z

Other articles of this Issue 3/2015

Clinical Reviews in Allergy & Immunology 3/2015 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.